The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Factors to consider when choosing between cilta-cel & ide-cel for patients with multiple myeloma
Eric Jurgens, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of factors to consider when choosing between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for patients with multiple myeloma, including availability of these agents and their respective side effect profiles. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
